WO2010060934A3 - Protéines cnnm et utilisations de celles-ci - Google Patents

Protéines cnnm et utilisations de celles-ci Download PDF

Info

Publication number
WO2010060934A3
WO2010060934A3 PCT/EP2009/065848 EP2009065848W WO2010060934A3 WO 2010060934 A3 WO2010060934 A3 WO 2010060934A3 EP 2009065848 W EP2009065848 W EP 2009065848W WO 2010060934 A3 WO2010060934 A3 WO 2010060934A3
Authority
WO
WIPO (PCT)
Prior art keywords
cnnm
proteins
cnnm1
cnnm2
cnnm4
Prior art date
Application number
PCT/EP2009/065848
Other languages
English (en)
Other versions
WO2010060934A2 (fr
Inventor
Daniel François SCHORDERET
Pascal André ESCHER
Bozena Karolina Polok
Original Assignee
Ecole Polytechnique Federale De Lausanne (Epfl)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ecole Polytechnique Federale De Lausanne (Epfl) filed Critical Ecole Polytechnique Federale De Lausanne (Epfl)
Publication of WO2010060934A2 publication Critical patent/WO2010060934A2/fr
Publication of WO2010060934A3 publication Critical patent/WO2010060934A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/18—Dental and oral disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des protéines du groupe constitué de CNNM1, CNNM2, CNNM3 et CNNM4, des dérivés ou des fragments de celles-ci pour utilisation en tant que médicament, pour des applications de traitement et/ou de diagnostic. L’invention concerne en outre une séquence d’ADN génomique humain, ADNc ou ARNm codant pour une protéine fonctionnelle choisie dans le groupe constitué de CNNM1, CNNM2, CNNM3 et CNNM4 et des dérivés ou fragments fonctionnels de celles-ci.
PCT/EP2009/065848 2008-11-25 2009-11-25 Protéines cnnm et utilisations de celles-ci WO2010060934A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11775008P 2008-11-25 2008-11-25
US61/117,750 2008-11-25

Publications (2)

Publication Number Publication Date
WO2010060934A2 WO2010060934A2 (fr) 2010-06-03
WO2010060934A3 true WO2010060934A3 (fr) 2010-07-29

Family

ID=42123173

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/065848 WO2010060934A2 (fr) 2008-11-25 2009-11-25 Protéines cnnm et utilisations de celles-ci

Country Status (1)

Country Link
WO (1) WO2010060934A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003008557A2 (fr) * 2001-07-19 2003-01-30 University Of Florida Activateurs de kinases dependant des cyclines
WO2007130423A2 (fr) * 2006-05-01 2007-11-15 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Marqueurs biologiques de tissu de plaie chronique et méthodes d'utilisation pour des critères de débridement chirurgical

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003008557A2 (fr) * 2001-07-19 2003-01-30 University Of Florida Activateurs de kinases dependant des cyclines
WO2007130423A2 (fr) * 2006-05-01 2007-11-15 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Marqueurs biologiques de tissu de plaie chronique et méthodes d'utilisation pour des critères de débridement chirurgical

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DOWNEY L.M. ET AL.: "Identification of a locus on chromosome 2q11 at which recessive amelogenesis imperfecta and cone-rod dystrophy cosegregate.", EUR. J. HUM. GENET., vol. 10, 2002, pages 865 - 869, XP002581334 *
GOYTAIN ANGELA ET AL: "Functional characterization of ACDP2 (ancient conserved domain protein), a divalent metal transporter", PHYSIOLOGICAL GENOMICS, AMERICAN PHYSIOLOGICAL SOCIETY, US LNKD- DOI:10.1152/PHYSIOLGENOMICS.00058.2005, vol. 22, no. 3, 11 August 2005 (2005-08-11), pages 382 - 389, XP002535555, ISSN: 1094-8341 *
GUO D. ET AL.: "Physical interaction and functional coupling between ACDP4 and te intracellular chaperone COXII, an implication of the role of ACDP4 in essentila metal ion transport and homeostasis.", MOLECULAR PAIN, vol. 1, 15, April 2005 (2005-04-01), XP002581333 *
MICHAELIDES M. ET AL.: "Progressive cone and cone-rod dystrophies : phenotypes and underlying molecular genetic basis.", SURVEY OF OPHTHALMOLOGY, vol. 51, no. 3, 2006, pages 232 - 258, XP002581335 *
WANG C-Y ET AL: "Molecular cloning and characterization of a novel gene family of four ancient conserved domain proteins (ACDP)", GENE, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/S0378-1119(02)01210-6, vol. 306, 13 March 2003 (2003-03-13), pages 37 - 44, XP004416777, ISSN: 0378-1119 *

Also Published As

Publication number Publication date
WO2010060934A2 (fr) 2010-06-03

Similar Documents

Publication Publication Date Title
WO2008142164A3 (fr) Séquences d'acides aminés dirigées contre rank-l et polypeptides comprenant ces dernières, destinés au traitement de maladies et affections osseuses
WO2007009894A3 (fr) Nouveaux peptides utilises dans le traitement de l'obesite
WO2007141274A3 (fr) Molécules de liaison humaines présentant une activité bactéricide contre les staphylocoques et leurs utilisations
WO2007104529A3 (fr) Séquences d'acides aminés dirigées contre il-6 et polypeptides incluant lesdites séquences dans le traitement de maladies et de troubles associés au signalement faisant intervenir il-6
WO2009080306A8 (fr) Compositions antipelliculaires contenant des peptides
WO2008087186A3 (fr) Nouveaux peptides pour le traitement de l'obésité
WO2007090569A8 (fr) Composition sanguine conditionnée et son procédé de préparation
WO2004075823A8 (fr) Derives de benzimidazole et d’imidazo-pyridine ayant une addinite pour les recepteurs des melanocortines et leur utilisation en tant que medicament
WO2008087190A3 (fr) Traitement de l'obésité au moyen de peptides combinés à une intervention chirurgicale
WO2008054540A3 (fr) Induction de réponses immunitaires au virus de la grippe en utilisant des compositions de polypeptides et d'acides nucléiques
WO2010057112A3 (fr) Variants génétiques intervenant dans la cognition humaine et leurs procédés d'utilisation comme cibles diagnostiques et thérapeutiques
WO2009070294A3 (fr) Inhibition du récepteur de la protéine stimulant les macrophages (ron) et procédés de traitement
WO2010010551A3 (fr) Nouveaux peptides dérivés de l’angiopoïétine
WO2006128041A3 (fr) Compositions et procedes destines a traiter ou a prevenir un neoplasme chimiomoresistant
WO2009040420A3 (fr) Utilisation d'un monoterpène pour accroître une réparation tissulaire
WO2007125105A3 (fr) Activateurs de la glucokinase benzamidique
WO2008087188A3 (fr) Nouveaux peptides pour le traitement de l'obésité
WO2012083302A3 (fr) Compositions et procédés pour le traitement ou la prévention d'une infection par l'adénovirus 36 humain
WO2009106819A3 (fr) Matériaux biologiques et leurs utilisations
WO2009062576A3 (fr) Nouveaux dérivés de benzimidazole-dihydrothiadiazinone en tant que des inhibiteurs de la fructose-1,6-bisphosphatase, et compositions pharmaceutiques les comprenant
WO2008087189A3 (fr) Nouveaux peptides pour le traitement de l'obésité
WO2010011994A3 (fr) Polypeptides et leurs utilisations
WO2009147658A3 (fr) Compositions et procédés pour le diagnostic, le pronostic et le traitement d'un mésothéliome
WO2009037183A3 (fr) Préparation cosmétique et/ou pharmaceutique contenant des acides nucléiques destinée à la production de peptides antimicrobiens dans des tissus épithéliaux
WO2008015380A3 (fr) Protéine membranaire intégrale

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09756752

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09756752

Country of ref document: EP

Kind code of ref document: A2